Search | Clinical Trials Finder

Conditions: Delirium
Interventions: Intravenous Dexmedetomidine, Sublingual Dexmedetomidine, Intravenous Placebo, Sublingual Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 14
States / cities: Los Angeles, California • San Francisco, California • Chicago, Illinois + 9 more

Conditions: Blunt Injury of Thorax, Multiple Rib Fractures, Involving Three Ribs
Interventions: Ketamine 1 Mg/mL-NaCl 0.9% Intravenous Solution; Drug
Lead sponsor: North Memorial Health Care; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Robbinsdale, Minnesota

Conditions: Low Back Pain
Interventions: Caudal Epidural Injection, percutaneous adhesiolysis; Procedure
Lead sponsor: Pain Management Center of Paducah; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Paducah, Kentucky

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2
Interventions: Aerolized Hydroxychloroquine Sulfate, Placebo; Drug · Other
Lead sponsor: Pulmoquine Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Osteoarthritis
Interventions: Dextrose Prolotherapy, Saline Prolotherapy, At-home physical therapy exercise group; Procedure · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 40 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 2
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia
Interventions: Uproleselan, Placebo; Drug
Lead sponsor: GlycoMimetics Incorporated; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 30
States / cities: La Jolla, California • Los Angeles, California • Orange, California + 23 more

Conditions: Bowel Obstruction
Interventions: IV morphine sulfate, EXPAREL (bupivacaine liposome injectable suspension); Drug
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Riverdale, Georgia

Conditions: HIV Infections
Interventions: BMS-936559, Placebo for BMS-936559; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 5
States / cities: Aurora, Colorado • St Louis, Missouri • Chapel Hill, North Carolina + 2 more

Conditions: Critical Limb Ischemia
Interventions: RJX, Placebo; Drug
Lead sponsor: Reven Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Influenza
Interventions: Placebo, Cold-adapted live attenuated influenza virus vaccine, trivalent, Trivalent inactivated influenza vaccine; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 6
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia • St Louis, Missouri + 3 more

Conditions: Chronic Kidney Disease
Interventions: LY3113593, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 5
States / cities: Orlando, Florida • Indianapolis, Indiana • Shreveport, Louisiana + 2 more

Conditions: Cytomegalovirus Infection
Interventions: mRNA-1647, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 16 Years to 40 Years · Female only
Enrollment: 7,454 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 181
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 141 more

Conditions: Insulin Resistance
Interventions: Hypertonic Saline (3% NaCl), Isotonic Saline (0.9% NaCl); Other
Lead sponsor: University of Arkansas, Fayetteville; Other
Eligibility: 30 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Stroke
Interventions: NTx™-265: rhCG, then rEPO, Saline Placebo; Drug
Lead sponsor: Stem Cell Therapeutics Corp.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Newport Beach, California • Orange, California

Conditions: Atrial Fibrillation
Interventions: Bupivacaine, Saline; Drug · Other
Lead sponsor: Christopher Connors, MD; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Portland, Maine

Conditions: Hip Fractures
Interventions: Tranexamic acid, Normal Saline; Drug
Lead sponsor: Community Memorial Health System; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Ventura, California

Conditions: Pain
Interventions: Ketamine 0.15mg/kg, Ketamine 0.3mg/kg, Placebo; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Injection Site Irritation, Injection Site Bruising, Injection Site Discomfort, Benzoic Acid Adverse Reaction, Anesthesia, Local
Interventions: Sodium Chloride 0.9% Inj, Bacteriostatic Sodium Chloride 0.9 % INJECTION VIAL (ML); Drug
Lead sponsor: Jeffrey Alan Klein, MD; Industry
Eligibility: 16 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: San Juan Capistrano, California

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Arformoterol Tartrate Inhalation Solution, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 45 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 4
States / cities: Medford, Oregon • Portland, Oregon • Philadelphia, Pennsylvania + 1 more

Conditions: Spinal Cord Injury
Interventions: Zoledronic acid, normal saline 0.9%; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mixed Dyslipidemia
Interventions: ARO-ANG3, Placebo; Drug
Lead sponsor: Arrowhead Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 13
States / cities: Huntington Park, California • Hialeah, Florida • Miami, Florida + 10 more

Conditions: Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions: Aminophylline, Placebo; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypotension
Interventions: Attending real-time decision support, In-room real-time decision support, Attending feedback emails, In-room provider feedback emails, Anesthesia Information Management System (AIMS), Perioperative Data Warehouse (PDW), General anesthesia, Pager system, Central neuraxial anesthesia, Non-cardiac surgery, Propofol, Sevoflurane, Desflurane, Isoflurane, Ephedrine, Phenylephrine, Norepinephrine, Epinephrine, Dobutamine, Dopamine, Isoproterenol, Milrinone, Atropine, Glycopyrrolate, Vasopressin, Terlipressin, Sodium Chloride 0.9%, Ringer's lactate, Hydroxyethyl starch solutions, Fresh Frozen Plasma, Packed Red Blood Cells, Albumin solutions, Plasma-Lyte, Lidocaine, Bupivacaine, Levobupivacaine, Ropivacaine, Mepivacaine, Tetracaine, Prilocaine, Procaine, Chloroprocaine, Benzocaine, Articaine; Procedure · Device · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 60 Years to 100 Years
Enrollment: 22,435 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Search by objective public record fields.

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep (MINDDS II)

Low Dose Ketamine for Blunt Thoracic Trauma

A Randomized, Equivalence Trial of Percutaneous Lumbar Adhesiolysis and Caudal Epidural Steroid Injections

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Orally Inhaled Aerosolized Hydroxychloroquine Sulfate in Healthy Adult Volunteers

Joint Injections for Osteoarthritic Knee Pain

Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

Adult Patients Undergoing Open Colectomy MA402S23B303

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

A Safety and Tolerability Study of RJX Drug Product in Healthy Participants

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

A Study of LY3113593 in Participants With Chronic Kidney Disease

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

The Effect of Vasopressin on Glucose Regulation

REGENESIS (US): A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx™-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischemic Stroke Patients

Study to Evaluate the Effectiveness of SGB in Preventing Post-op Atrial Fibrillation

Blood Loss After Early TXA in Hip Fractures.

Low Dose Ketamine for Management of Acute Severe Pain in the Emergency Department

Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline

Efficacy Safety Study of Arformoterol QD Dosing Versus BID Dosing in COPD

Zoledronic Acid in Acute Spinal Cord Injury

Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

Decision Support for Intraoperative Low Blood Pressure

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy